Copied to clipboard!

IMC-F106C-101 dose escalation

Brenetafusp is an ImmTAC bispecific (PRAME×CD3) targeting the cancer testis antigen PRAME. In this phase 1 study (NCT04262466), 126 HLA-A*02:01+ patients with advanced solid tumors received weekly IV doses from 0.3-320 mcg. The primary objective was to identify the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D); additional objectives included pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity. Brenetafusp demonstrated manageable safety and preliminary efficacy in PRAME+ tumors. A phase 3 trial in metastatic cutaneous melanoma is ongoing

Type: Transcriptome Sequencing
Archive: European Genome-phenome Archive (EGA)

1 Dataset

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD50000002860	216 paired FASTQ files (108 samples). RNA was extracted from the blood at baseline from 108 patients on the NCT04262466 Phase 1 brenetafusp trial, and prepared for sequencing following Oligo-dT selection. Sequencing was performed on an Illumina NovaSeq X sequencer.	Illumina NovaSeq X	108